Differential impact of selective serotonin reuptake inhibitors on platelet response to clopidogrel: A randomized, double-blind, crossover trial

Pharmacotherapy

Volumn 35, Issue 2, 2015, Pages 140-147

  Rokach, Bruria Hirsh ^a   Spectre, Galia ^a   Shai, Ela ^a   Lotan, Amit ^a   Ritter, Amit ^a   Al Aieshy, Fadiea ^b   Malmström, Rickard E ^b   Varon, David ^a   Alcalai, Ronny ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

antiplatelets; clopidogrel; cytochrome P450; pharmacodynamics; selective serotonin reuptake inhibitors

Indexed keywords

ADENOSINE DIPHOSPHATE; CITALOPRAM; CLOPIDOGREL; COLLAGEN; CYTOCHROME P450 2C19; FLUVOXAMINE; SEROTONIN; VASODILATOR STIMULATED PHOSPHOPROTEIN; ANTITHROMBOCYTIC AGENT; CYP2C19 PROTEIN, HUMAN; CYTOCHROME P450 2C19 INHIBITOR; PRODRUG; SEROTONIN UPTAKE INHIBITOR; TICLOPIDINE;

ADULT; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG DETERMINATION; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; DRUG RESPONSE; ENZYME INHIBITION; ENZYME MECHANISM; ENZYME METABOLISM; FLOW CYTOMETRY; HUMAN; LOADING DRUG DOSE; MALE; NORMAL HUMAN; PLATELET AGGREGATION ASSAY; PLATELET REACTIVITY; PROTEIN PHOSPHORYLATION; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE AGGREGATION; ANALOGS AND DERIVATIVES; COMPARATIVE STUDY; DRUG EFFECTS; DRUG INTERACTION; METABOLISM; MIDDLE AGED; YOUNG ADULT;

ADULT; CITALOPRAM; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP2C19; CYTOCHROME P-450 CYP2C19 INHIBITORS; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; FLUVOXAMINE; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PRODRUGS; SEROTONIN UPTAKE INHIBITORS; TICLOPIDINE; YOUNG ADULT;

EID: 84923271570     PISSN: 02770008     EISSN: 18759114     Source Type: Journal    
DOI: 10.1002/phar.1542     Document Type: Article

References (32)

1. Sofi F, Marcucci R, Gori AM, Giusti B, Abbate R, Gensini GF,. Clopidogrel non-responsiveness and risk of cardiovascular morbidity. An updated meta-analysis. Thromb Haemost 2010; 103: 841-8.
2. Collet JP, Hulot JS, Anzaha G, et al. High doses of clopidogrel to overcome genetic resistance: the randomized crossover CLOVIS-2 (Clopidogrel and Response Variability Investigation Study 2). JACC Cardiovasc Interv 2011; 4: 392-402.
3. Lee JM, Park S, Shin DJ, et al. Genetic polymorphisms in the cytochrome P450 gene with clopidogrel resistance after drug-eluting stent implantation in Koreans. Am J Cardiol 2009; 104: 46-51.
4. Furuta T, Iwaki T, Umemura K,. Influences of different proton pump inhibitors on the anti-platelet function of clopidogrel in relation to CYP2C19 genotypes. Br J Clin Pharmacol 2010; 70: 383-92.
5. Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT,. Cytochrome P-450 polymorphisms and response to clopidogrel. N Engl J Med 2009; 360: 354-62.
6. Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009; 360: 363-75.
7. Scott SA, Sangkuhl K, Stein CM, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy: 2013 Update. Clin Pharmacol Ther 2013; 94 (3): 317-23.
8. Juurlink DN, Gomes T, Ko DT, et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 2009; 180: 713-8.
9. Ho PM, Maddox TM, Wang L, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 2009; 301: 937-44.
10. Gilard M, Arnaud B, Cornily JC, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole Clopidogrel Aspirin) study. J Am Coll Cardiol 2008; 51: 256-60.
11. Information for Healthcare Professionals: Update to the labeling of Clopidogrel Bisulfate (marketed as Plavix) to alert healthcare professionals about a drug interaction with omeprazole (marketed as Prilosec and Prilosec OTC). Available From: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm190787.htm Accessed 17 November 2009.
12. Frasure-Smith N, Lesperance F, Talajic M,. Depression and 18-month prognosis after myocardial infarction. Circulation 1995; 91: 999-1005.
13. Glassman AH, O'Connor CM, Califf RM, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA 2002; 288: 701-9.
14. Lespérance F, Frasure-Smith N, Talajic M, Bourassa MG,. Five-year risk of cardiac mortality in relation to initial severity and one-year changes in depression symptoms after myocardial infarction. Circulation 2002; 105: 1049-1053.
15. Andrade C, Sandarsh S, Chethan KB, Nagesh KS,. Serotonin reuptake inhibitor antidepressants and abnormal bleeding: a review for clinicians and reconsideration of mechanisms. J Clin Psychiatry 2010; 71: 1565-1575.
16. De Abajo F, Garcia-Rodriguez L, Montero D,. Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding; population based case-control study. BMJ 1999; 319: 1106-9.
17. van Zyl LT, Lespérance F, Frasure-Smith N, et al. Platelet and endothelial activity in comorbid major depression and coronary artery disease patients treated with citalopram: the Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy Trial (CREATE) biomarker sub-study. J Thromb Thrombolysis 2009; 27: 48-56.
18. McCloskey DJ, Postolache TT, Vittone BJ, et al. Selective serotonin reuptake inhibitors: measurement of effect on platelet function. Transl Res 2008; 151: 168-72.
19. Serebruany VL,. Selective serotonin reuptake inhibitors and increased bleeding risk: are we missing something? Am J Med 2006; 119: 113-6.
20. Meijer WE, Heerdink ER, Nolen WA, Herings RM, Leufkens HG, Egberts AC,. Association of risk of abnormal bleeding with degree of serotonin reuptake inhibition by antidepressants. Arch Intern Med 2004; 164: 2367-70.
21. Opatrny L, Delaney JA, Suissa S,. Gastro-intestinal haemorrhage risks of selective serotonin receptor antagonist therapy: a new look. Br J Clin Pharmacol 2008; 66: 76-81.
22. Labos C, Dasgupta K, Nedjar H, Turecki G, Rahme E,. Risk of bleeding associated with combined use of selective serotonin reuptake inhibitors and antiplatelet therapy following acute myocardial infarction. CMAJ 2011; 183: 1835-43.
23. Spina E, Santoro V, D'Arrigo C,. Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update. Clin Ther 2008; 30: 1206-27.
24. Rasmussen BB, Nielsen TL, Brøsen K,. Fluvoxamine inhibits the CYP2C19-catalysed metabolism of proguanil in vitro. Eur J Clin Pharmacol 1998; 54: 735-40.
25. Jeppesen U, Gram LF, Vistisen K, Loft S, Poulsen HE, Brøsen K,. Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. Eur J Clin Pharmacol 1996; 51: 73-8.
26. Delavenne X, Magnin M, Basset T, et al. Investigation of drug-drug interactions between clopidogrel and fluoxetine. Fundam Clin Pharmacol 2013; 27: 683-9.
27. Angiolillo DJ, Gibson CM, Cheng S, et al. Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies. Clin Pharmacol Ther 2011; 89: 65-74.
28. Karon BS, Jaben E,. Laboratory methods for evaluating effectiveness of anti-platelet therapy. Clin Lab News 2011; 37: 8-10.
29. von Bahr C, Ursing C, Yasui N, Tybring G, Bertilsson L, Röjdmark S,. Fluvoxamine but not citalopram increases serum melatonin in healthy subjects-an indication that cytochrome P450 CYP1A2 and CYP2C19 hydroxylate melatonin. Eur J Clin Pharmacol 2000; 56: 123-7.
30. Papakostas GI, Charles D, Fava M,. Are typical starting doses of the selective serotonin reuptake inhibitors sub-optimal? A meta-analysis of randomized, double-blind, placebo-controlled, dose-finding studies in major depressive disorder. World J Biol Psychiatry 2010; 11: 300-7.
31. Burkard T, Kaiser CA, Brunner-La Rocca H, Osswald S, Pfisterer ME, Jeger RV,. Combined clopidogrel and proton pump inhibitor therapy is associated with higher cardiovascular event rates after percutaneous coronary intervention: a report from the BASKET trial. J Intern Med 2012; 271: 257-263.
32. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Variability to individual responsiveness to clopidogrel clinical implication, management, and future perspectives. J Am Coll Cardiol 2007; 49: 1505-16.